Literature DB >> 25895485

Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.

Ivan Stevic1, Tom C Dembinski1, K Alok Pathak2, William D Leslie3.   

Abstract

OBJECTIVES: Treatment of differentiated thyroid cancer (DTC) includes surgical thyroidectomy and, in most cases, radioactive iodine (RAI) ablation. Measurement of serum thyroglobulin (Tg) levels is used for assessing disease burden and identifying persistent-recurrent DTC. This prospective study determined the Tg profile before and after RAI-ablation in patients with DTC. DESIGN AND METHODS: Fifty-five DTC patients with complete resection received RAI-ablation and were assessed for Tg at baseline (non-stimulated), pre-ablation (stimulated), 7 days post-ablation (stimulated) and at 6 months (stimulated). Stimulation of Tg was achieved by thyroid hormone withdrawal to achieve serum thyroid stimulating hormone (TSH) ≥30 mU/L. Thyroid remnant size was estimated from whole body scintigraphy. Similar protocols were implemented for nine patients with incomplete resection/metastatic disease for comparison.
RESULTS: Mean stimulated Tg levels for DTC patients with complete resection at 7 days post-RAI increased 13-fold from 13.7 to 175.5 μg/L (p<0.0001), and the Tg levels reduced to 2.3 μg/L (p<0.0001 versus post-RAI) by follow-up. None of the patients had recurrence of disease. For the nine patients with incomplete resection/metastases, Tg levels were higher throughout compared to the patients with complete resection. There was no increase in Tg between pre- and post-RAI. We did not observe a significant correlation between the remnant size and Tg increase.
CONCLUSIONS: This study confirms a prominent transient early increase in Tg post-RAI ablation in DTC patients with complete resection, with the Tg levels falling below baseline by 6 months. This is presumed to reflect RAI-induced thyroid tissue destruction/inflammation with subsequent release of Tg from the thyroid remnant. Recognizing this transient phenomenon is important for post-ablation Tg interpretation and patient management.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Radioactive iodine ablation; Thyroglobulin; Thyroid cancer; Thyroid remnant

Mesh:

Substances:

Year:  2015        PMID: 25895485     DOI: 10.1016/j.clinbiochem.2015.04.009

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  EVALUATION OF CARDIOVASCULAR RISK AND MYOCARDIAL PERFUSION IN PATIENTS WITH RADICALLY TREATED DIFFERENTIATED THYROID CARCINOMA AND REPEATED EPISODES OF IATROGENIC HYPOTHYROIDISM.

Authors:  M Saftencu; E Barbus; C Pestean; A Piciu; D Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jan-Mar       Impact factor: 0.877

2.  Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.

Authors:  Yansong Lin; Chen Wang; Wen Gao; Ruixue Cui; Jun Liang
Journal:  Oncotarget       Date:  2017-06-27

Review 3.  The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.

Authors:  Sha Li; Chutong Ren; Yi Gong; Fei Ye; Yulong Tang; Jiangyue Xu; Can Guo; Jiangsheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

4.  Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma.

Authors:  Su Woong Yoo; Md Sunny Anam Chowdhury; Subin Jeon; Sae-Ryung Kang; Sang-Geon Cho; Jahae Kim; Changho Lee; Young Jae Ryu; Ho-Chun Song; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.